{"url":"https://newsforagent.com/news/2026-11-04/neion-bio-john-maga-biologics-cmc","markdown_url":"https://newsforagent.com/news/2026-11-04/neion-bio-john-maga-biologics-cmc.md","title":"Neion Bio Names John Maga Head of Biologics and CMC","headline":"Neion Bio Appoints BioMarin Veteran John Maga to Lead Biologics and CMC","description":"Neion Bio appointed John Maga, a 25-year biopharma veteran with nearly 15 years at BioMarin, as Head of Biologics and CMC to expand its Raptor platform.","section":"Leadership","published_at":"2026-11-04T17:28:51+00:00","modified_at":"2026-11-04T17:28:51+00:00","author":"News Desk","key_takeaways":["John A. Maga, Ph.D., joined Neion Bio as Head of Biologics and CMC, bringing more than 25 years of biopharmaceutical development experience.","Maga spent nearly 15 years at BioMarin Pharmaceutical, where he held senior leadership roles across analytical and process sciences.","Neion Bio's Raptor platform uses precision genetic engineering to produce recombinant proteins in the egg white of transgenic chickens."],"companies":[{"name":"Neion Bio","is_primary":true,"profile_url":"https://akta.pro/company-profiles/02c24td/neion-bio","website":"https://www.neionbio.com"}],"source":{"publisher":"GlobeNewswire","title":"Neion Bio Taps John Maga as Head of Biologics and CMC to Expand Capabilities In Innovative Development","url":"https://www.globenewswire.com/news-release/2026/11/04/3395677/0/en/neion-bio-taps-john-maga-as-head-of-biologics-and-cmc-to-expand-capabilities-in-innovative-development.html"},"other_sources":[],"tags":["Leadership","Neion Bio"],"body_markdown":"Neion Bio appointed John A. Maga, Ph.D., as Head of Biologics and CMC, the company said in a [GlobeNewswire](https://www.globenewswire.com/news-release/2026/11/04/3395677/0/en/neion-bio-taps-john-maga-as-head-of-biologics-and-cmc-to-expand-capabilities-in-innovative-development.html) announcement on November 4, 2026. Maga brings more than 25 years of biopharmaceutical development experience, including nearly 15 years at BioMarin Pharmaceutical, where he held senior leadership roles across analytical and process sciences.\n\n## Maga's Role Leading Biologics Development\n\nAt [Neion Bio](https://akta.pro/company-profiles/02c24td/neion-bio), Maga will lead biologics development and help expand the company's capabilities to support partners co-developing complex and differentiated therapeutic proteins. The company's Raptor platform uses precision genetic engineering to produce recombinant proteins in the egg white of transgenic chickens.\n\nSam Levin, Co-Founder and Chief Technology Officer of Neion Bio, said: \"John brings deep experience solving the development challenges that determine whether promising biologics can be manufactured robustly and advanced successfully. He will help us expand those capabilities and work with partners to explore where Raptor can bring meaningful advantages to their programs.\"\n\nAt BioMarin, Maga built and led development organizations spanning oligonucleotides, gene therapies, recombinant proteins, monoclonal antibodies, peptides, and small molecules, guiding programs from early development through commercial approval. His work included steering technical and regulatory strategy behind two commercial approvals, alongside major regulatory filings and the growth of teams and capabilities across the CMC organization. He joined BioMarin in 2010 when the company acquired ZyStor Therapeutics, where he had spent the previous decade developing protein targeting technologies for lysosomal storage diseases and advancing the company's lead program to an open IND, following earlier work at Symbiontics.\n\nMaga said: \"What excites me about the Raptor platform is that it opens up an entirely new realm of biological possibility. I believe it has the potential to transform the biotech industry, not just through scale, cost and resiliency, but by enabling new approaches to biologic development itself.\"\n\n## Neion Bio's Recent Leadership and Funding Moves\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Neion Bio appointed Ming Li as President of Commercial Operations in April 2026, hiring the former CSO of Alvotech who spearheaded its IPO and led more than 80 transactions. The same records show the company appointed James Kehler, V.M.D., Ph.D., former VP at Colossal Biosciences, as Head of Avian Sciences in April 2026 to lead the avian genetics and stem cell biology program underlying the Raptor platform.\n\nThe company closed an oversubscribed $23 million Series A led by Caffeinated Capital in June 2026 to scale the Raptor platform, bringing total funding to approximately $34 million, according to the same records. Neion Bio was founded in 2024 and is headquartered in New York.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}